Trial Profile
Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetics Study in Adults of BSYX-A110, a Human Chimeric Anti-Staphylococcal Monoclonal Antibody for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pagibaximab (Primary)
- Indications Sepsis; Staphylococcal infections
- Focus Adverse reactions
- Sponsors Biosynexus
- 24 Sep 2014 New trial record